GenAI Driven R&D Transformation
Rebuilding Pharma R&D for a GenAI-Driven Future
to
40%
faster patient recruitment
26 weeks
to 4 weeks reduction in regulatory submission timelines
Earlier
identification and mitigation of operational and compliance risks
More informed
data-driven decisions across clinical, regulatory, and medical functions
Greater return
on R&D investments through accelerated value realization
Rebuilding Pharma R&D for a GenAI-Driven Future
Everest Group Recognizes Indegene as a Front-Runner in GenAI Life Sciences Market Adoption
AI-driven pharma innovation depends on trust and responsible oversight.
Speak to our experts today.